Philip Meuleman focuses on Virology, Hepatitis C virus, Virus, Immunology and Cell culture. His Virology study frequently draws connections between adjacent fields such as Genotype. His study in Hepatitis C virus is interdisciplinary in nature, drawing from both Liver transplantation, Transplantation, Viral hepatitis, Hepatitis C and Liver disease.
His work in Immunology addresses issues such as In vivo, which are connected to fields such as Viral disease, Internal medicine, Viral life cycle and Hepatology. His Antibody research includes elements of Immune system and Immunity. His Infectivity study combines topics from a wide range of disciplines, such as Receptor and Molecular biology.
Philip Meuleman spends much of his time researching Virology, Hepatitis C virus, Immunology, Virus and In vivo. Philip Meuleman combines subjects such as Genotype, Hepatitis E virus, Antibody, Monoclonal antibody and Transplantation with his study of Virology. His studies deal with areas such as Hepatocellular carcinoma, Viral entry, Hepatitis C and Liver transplantation as well as Hepatitis C virus.
His biological study spans a wide range of topics, including Human liver and Liver disease. His Virus study integrates concerns from other disciplines, such as Cell culture and Green fluorescent protein. His In vivo study combines topics in areas such as In vitro, Hepatocyte, Drug metabolism, Metabolism and Plasmodium falciparum.
His main research concerns Virology, Hepatitis E virus, Hepatitis C virus, Virus and Genotype. His Virology research incorporates elements of Human liver and Antibody, Immunology, Antigen. Philip Meuleman works mostly in the field of Immunology, limiting it down to concerns involving In vivo and, occasionally, Plasmodium falciparum.
His Hepatitis E virus research is multidisciplinary, incorporating elements of Ribavirin, Hepatitis E, Capsid and Transmission. His research in Hepatitis C virus intersects with topics in Hepatitis C, Liver disease, Epitope, Monoclonal antibody and Transplantation. In Virus, he works on issues like Chimera, which are connected to Vector.
Philip Meuleman mostly deals with Virology, Hepatitis E virus, Hepatitis C virus, Genotype and Ribavirin. His work in the fields of Virology, such as Virus and Antiviral therapy, overlaps with other areas such as Small animal. Many of his studies on Virus apply to Hepatitis C as well.
His work deals with themes such as Viral hepatitis, Hepatitis E, In vivo and Transmission, which intersect with Hepatitis E virus. Philip Meuleman interconnects Hepatocellular carcinoma and Plasmodium falciparum infection in the investigation of issues within Hepatitis C virus. His Genotype research includes themes of Human liver and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
Brett D. Lindenbach;Philip Meuleman;Alexander Ploss;Thomas Vanwolleghem.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.
Philip Meuleman;Louis Libbrecht;Rita De Vos;Bernard de Hemptinne.
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo.
Philip Meuleman;Joseph Hesselgesser;Matthew Paulson;Thomas Vanwolleghem.
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
Sandra Ciesek;Thomas von Hahn;Che C. Colpitts;Luis M. Schang.
Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant
Artur Kaul;Ilka Woerz;Philip Meuleman;Geert Leroux-Roels.
Journal of Virology (2007)
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity
Joe Grove;Thierry Huby;Zania Stamataki;Thomas Vanwolleghem.
Journal of Virology (2007)
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.
Thomas Vanwolleghem;Jens Bukh;Jens Bukh;Jens Bukh;Philip Meuleman;Isabelle Desombere.
The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV
Philip Meuleman;Geert Leroux-Roels.
Antiviral Research (2008)
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations.
Thomas Pietschmann;Margarita Zayas;Philip Meuleman;Gang Long.
PLOS Pathogens (2009)
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation
Samira Fafi-Kremer;Isabel Fofana;Isabel Fofana;Eric Soulier;Eric Soulier;Patric Carolla;Patric Carolla.
Journal of Experimental Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: